DNA methylation as a therapeutic target in hematologic disorders: recent results in older patients with myelodysplasia and acute myeloid leukemia
B Rüter, PW Wijermans, M Lübbert - International journal of hematology, 2004 - Springer
DNA methylation provides a major epigenetic code (besides histone modification) of the
lineage-and developmentspecific genes (such as regulators of differentiation in the …
lineage-and developmentspecific genes (such as regulators of differentiation in the …
DNA methylation changes in hematologic malignancies: biologic and clinical implications.
DNA methylation changes are among the most common detectable abnormalities in human
neoplasia. Hypermethylation within the promoters of selected genes appears to be …
neoplasia. Hypermethylation within the promoters of selected genes appears to be …
Inhibitors of DNA methylation in the treatment of hematological malignancies and MDS
DNA methylation abnormalities have recently emerged as one of the most frequent
molecular changes in hematopoietic neoplasms. Since methylation and transcriptional …
molecular changes in hematopoietic neoplasms. Since methylation and transcriptional …
The DNA methylation landscape of hematological malignancies: an update
P Blecua, L Martinez‐Verbo, M Esteller - Molecular Oncology, 2020 - Wiley Online Library
The rapid advances in high‐throughput sequencing technologies have made it more evident
that epigenetic modifications orchestrate a plethora of complex biological processes. During …
that epigenetic modifications orchestrate a plethora of complex biological processes. During …
[HTML][HTML] Role of epigenetic changes in hematological malignancies
U Lehmann, K Brakensiek, H Kreipe - Annals of hematology, 2004 - Springer
Inactivation of tumor suppressor genes is an important event contributing to the development
of neoplasia. In addition to the classic genetic mechanisms of deletion or inactivating point …
of neoplasia. In addition to the classic genetic mechanisms of deletion or inactivating point …
DNA methylation in normal and malignant hematopoiesis
The study of DNA methylation has been a rapidly expanding field since its dawn in the
1960s. DNA methylation is an epigenetic modification that plays a crucial role in guiding the …
1960s. DNA methylation is an epigenetic modification that plays a crucial role in guiding the …
DNA methylation as a therapeutic target in cancer
JPJ Issa - Clinical Cancer Research, 2007 - AACR
Targeting DNA methylation for cancer therapy has had a rocky history. The first reports on
DNA methylation changes in cancer described global loss of methylation, which has been …
DNA methylation changes in cancer described global loss of methylation, which has been …
Hypomethylating agents in the treatment of myelodysplastic syndromes and myeloid leukemia
A Szmigielska-Kaplon, T Robak - Current Cancer Drug Targets, 2011 - ingentaconnect.com
Epigenetic changes play an important role in cancer pathogenesis. Hypermethylation of
DNA generally results in decreased expression of tumor suppressor genes and defective …
DNA generally results in decreased expression of tumor suppressor genes and defective …
Clinical development of demethylating agents in hematology
SC Navada, J Steinmann, M Lübbert… - The Journal of …, 2014 - Am Soc Clin Investig
The term epigenetics refers to the heritable changes in gene expression that are not
associated with a change in the actual DNA sequence. Epigenetic dysregulation is linked to …
associated with a change in the actual DNA sequence. Epigenetic dysregulation is linked to …
MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation
ME Figueroa, L Skrabanek, Y Li… - Blood, The Journal …, 2009 - ashpublications.org
Increasing evidence shows aberrant hypermethylation of genes occurring in and potentially
contributing to pathogenesis of myeloid malignancies. Several of these diseases, such as …
contributing to pathogenesis of myeloid malignancies. Several of these diseases, such as …
相关搜索
- dna methylation therapeutic target
- dna methylation hematologic disorders
- dna methylation older patients
- dna methylation secondary aml
- dna methylation hematologic malignancies
- dna methylation in the treatment
- aberrant dna methylation
- dna methylation landscape
- inhibitors of dna methylation
- myeloid leukemia hypomethylating agents
- myeloid leukemia myelodysplastic syndromes
- demethylating agents clinical development
- hematologic disorders therapeutic target
- older patients therapeutic target
- older patients hematologic disorders